Pfizer's Xalkori, Sanofi’s Eloxatin Liver Cancer Indication Nearing Approval In China As CDE Gains Review Confidence
This article was originally published in The Pink Sheet Daily
Executive Summary
CDE recently published review summaries for Pfizer’s Xalkori (crizotinib) and the first liver cancer indication for Sanofi's Eloxatin (oxaliplatin), which means a nod from SFDA is expected soon.